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Deficient SOCS3 and SHP-1 Expression
in Psoriatic T Cells
Karsten W. Eriksen1,2, Anders Woetmann1,2, Lone Skov3, Thorbjørn Krejsgaard1,2, Lone F. Bovin4,
Mikkel L. Hansen1,2, Kirsten Grønbæk5, Nils Billestrup6, Mogens H. Nissen1, Carsten Geisler1,
Mariusz A. Wasik7 and Niels Ødum1,2
IFN-a and skin-infiltrating activated T lymphocytes have important roles in the pathogenesis of psoriasis. T cells
from psoriatic patients display an increased sensitivity to IFN-a, but the pathological mechanisms behind the
hyperresponsiveness to IFN-a remained unknown. In this study, we show that psoriatic T cells display deficient
expression of the suppressor of cytokine signaling (SOCS)3 in response to IFN-a and a low baseline expression
of the SH2-domain-containing protein-tyrosine phosphatase (SHP)-1 when compared with skin T cells from
nonpsoriatic donors. Moreover, IFN-a-stimulated psoriatic T cells show enhanced activation of JAKs (JAK1 and
TYK2) and signal transducers and activators of transcription. Increased expression of SOCS3 proteins resulting
from proteasomal blockade partially inhibits IFN-a response. Similarly, forced expression of SOCS3 and SHP-1
inhibits IFN-a signaling in psoriatic T cells. In conclusion, our data suggest that loss of regulatory control is
involved in the aberrant hypersensitivity of psoriatic T cells to IFN-a.
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INTRODUCTION
Psoriasis is an immune-mediated skin disease affecting 1–3%
of the population worldwide. It is characterized by abnormal
epidermal proliferation and chronic cutaneous inflammation
(Boyman et al., 2007; Nickoloff et al., 2007). Although
several types of immune cells and various mechanisms have
been implicated in the pathogenesis of psoriasis, the skin-
infiltrating activated T lymphocytes and the local over-
expression of proinflammatory cytokines clearly have pivotal
roles in the initiation and maintenance of the disease (Lew
et al., 2004; Di et al., 2009). Several lines of clinical and
experimental evidence suggest that IFN-a has an important
role in the pathogenesis of psoriasis. (Conlon et al., 1990;
Funk et al., 1991; Pauluzzi et al., 1993; Brenard, 1997;
Calvino et al., 1999; Erkek et al., 2000; Hida et al., 2000; van
der Fits et al., 2004; Nestle et al., 2005; Sonkoly et al., 2007).
IFN-a induces activation of JAKs (TYK2 and JAK1) bound to
IFN-a receptors, IFNAR1 and IFNAR2, respectively (Kotenko
and Pestka, 2000; Takaoka and Yanai, 2006) and subse-
quently induces activation of signal transducers and activa-
tors of transcription (STATs). Once activated, STAT1/STAT2
heterodimers, together with the IFN regulatory factor-9,
STAT3 and STAT4 homodimers, and/or STAT1/STAT3 hetero-
dimers bind to STAT-binding sequences in regulatory regions
of IFN-a-inducible genes, fostering their transcriptional
activation (Xu et al., 1996; Kotenko and Pestka, 2000;
Takaoka and Yanai, 2006).
Downregulation of cytokine-induced signaling pathways
after T-cell activation represents an important mechanism to
suppress prolonged cytokine responses that may otherwise
have harmful effects (Kisseleva et al., 2002; Veillette et al.,
2002; Alexander and Hilton, 2004). The suppressor of
cytokine signaling (SOCS) proteins constitute a family of
STAT-induced negative regulators of cytokine signaling
(Alexander and Hilton, 2004). By a classical negative
feedback loop, SOCS proteins bind directly to cytokine
receptors or to the catalytic domain of JAKs, and conse-
quently inhibit the recruitment and phosphorylation of STAT
proteins (Alexander and Hilton, 2004) or target the receptor
complex for ubiquitination and subsequent proteasome-
mediated degradation. IFN-a has been shown to induce the
expression of SOCS3 in human T cells (Brender et al., 2001b;
Zimmerer et al., 2007). Conversely, SOCS3 inhibits IFN-a-
mediated signaling (Song and Shuai, 1998; Brender et al.,
2001a, 2005; Zimmerer et al., 2007). Furthermore, the
involvement of SOCS3 in the negative regulation of IFN-a
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signaling was demonstrated in recent studies in patients with
chronic myelogenous leukemia, chronic hepatitis C virus
infection, and cutaneous T-cell lymphoma (Shen et al., 2000;
Hong et al., 2001; Brender et al., 2001a, 2005; Sakai et al.,
2002; Bode et al., 2003), in which constitutive expression of
SOCS3 conferred resistance to IFN-a treatment. Moreover,
SH2-domain-containing protein-tyrosine phosphatases, SHP-
1 and SHP-2, have been shown to negatively regulate
signaling meditated by cytokines including IFN-a by depho-
sphorylating cytokine receptors and receptor-associated
tyrosine kinases (You et al., 1999). The ‘‘moth-eaten’’ mice
that lack functional SHP-1 display severe dyshematopoiesis,
chronic activation of the immune system, and systemic
autoimmunity (Shultz et al., 1997). It is noteworthy that bone
marrow-derived macrophages from these mice exhibit
hyperactivation of IFN-a/b-induced JAK/STAT proteins (David
et al., 1995).
Recent observations indicate that T cells from psoriatic
patients display an increased sensitivity to IFN-a, leading to
increased STAT signaling and IFN-g production (Eriksen
et al., 2005). As IFNAR expression was similar in psoriatic
and nonpsoriatic T cells, the pathological mechanisms
behind the hyperresponsiveness to IFN-a remained unknown
(Eriksen et al., 2005). In this study, we provide evidence that
IFN-a hypersensitivity is associated with deficient expression
of the negative regulators of the IFN-a signaling pathway,
SOCS3 and SHP-1, and that an increased expression of these
regulators inhibits IFN-a signaling in psoriatic T cells.
RESULTS
Prolonged IFN-a-induced signaling correlates with deficient
induction of SOCS3
Sonkoly et al. (2007) recently reported on a deficient
expression of SOCS3 in keratinocytes from psoriatic epider-
mis. Therefore, we investigated whether the increased IFN-a
signaling in psoriatic T cells was due to a deficient expression
of SOCS3. As anticipated (Brender et al., 2001b), IFN-a
induced a rapid and robust expression of SOCS3 mRNA in
control T cells (Figure 1a). In contrast, IFN-a-mediated
SOCS3 mRNA induction was significantly weaker in psoriatic
T cells (Figure 1a, left). Although the SOCS3 response in
psoriatic and nonpsoriatic T cells displayed similar kinetics,
the level of SOCS3 mRNA in psoriatic T cells was lower at all
time points and up to 50% weaker than the induction in
control T cells (Figure 1a). Similar expression patterns were
observed in three different sets of psoriatic and nonpsoriatic T
cells (Figure 1b), indicating that the transcription of SOCS3
was differently regulated in psoriatic and nonpsoriatic T cells.
To determine whether these differences were also seen at
the protein level, total cell lysates from the experiments
described above were also subjected to western blotting
analysis. As shown in Figure 1c, IFN-a triggered a significant
SOCS3 protein expression in control T cells and the
expression pattern followed the above-described kinetics of
SOCS3 mRNA induction, seemingly with some degree of
delay (Figure 1c, right, vs Figure 1a, right); Thus, SOCS3
mRNA appeared at 15 minutes, whereas SOCS3 protein was
detectable at 30 minutes, and SOCS3 mRNA expression was
the most pronounced at 60 minutes, whereas SOCS3 protein
expression peaked after 120–240 minutes. Importantly, the
expression of SOCS3 protein was lower at all time points in
psoriatic T cells when compared with control T cells (Figure
1c, left). Indeed, only a faint SOCS3 band was detectable
after 60–120 minutes (Figure 1c). Importantly, the low SOCS3
expression in psoriatic T cells was associated with a
prolonged IFN-a-induced activation of STAT1, STAT2, and
STAT4 (Figure 1c, left, upper part). It is noteworthy that the
increase in SOCS3 protein expression after 60 minutes
coincided with a marked decrease in the level of tyrosine-
phosphorylated STAT proteins in control T cells (Figure 1c).
Essentially similar findings were observed in three sets of
psoriatic and nonpsoriatic T cells (data not shown). As shown
recently (Kohlmann et al., 2004), expansion of T cell lines
in culture might change the characteristics of the cells. Yet,
a deficient induction of SOCS3 was also seen in psoriatic
skin T cells cultured for a short (2 weeks) period of time
(Figure 1d), supporting our observations above that psoriatic
T cells display a deficient induction of SOCS3 expression in
response to IFN-a.
Increased SOCS3 expression inhibits IFN-a signaling
in psoriatic T cells
To examine whether IFN-a signaling in psoriatic T cells was
sensitive to inhibition by SOCS3, we undertook two
approaches: the first, to increase the level of endogenous
SOCS3, and the second, to induce high SOCS3 expression
using a transient transfection system. As endogenous SOCS3
protein is subjected to a rapid proteasomal degradation
(Sasaki et al., 2003), psoriatic T cells were incubated with the
proteasome inhibitor MG132 before stimulation with IFN-a.
As shown in Figure 2a, preincubation with MG132 signifi-
cantly upregulated SOCS3 expression. In contrast, the
expression of STAT proteins and MAP kinases (extracellular
signal-regulated kinase-1/2) remained unaffected, confirming
the previous findings that SOCS3 proteins are rapidly and
selectively degraded through the proteasomal pathway
(Sasaki et al., 2003). Importantly, the increase in SOCS3
protein expression was associated with a significant inhibi-
tion of IFN-a-induced STAT tyrosine phosphorylation. Next,
psoriatic T cells were transiently transfected with a hemag-
glutinin (HA)-tagged SOCS3 expression vector and analyzed
for IFN-a-triggered STAT1 phosphorylation by flow cytometry
in HA-positive transfected cells. To test the sensitivity of this
assay, psoriatic and control T cells were first stimulated with
different concentrations of IFN-a before flow cytometric
analysis of IFN-a-induced STAT1 phosphorylation. Indeed,
this assay could confirm the IFN-a hypersensitivity in
psoriatic T cells compared with control T cells (Figure 2b),
in which the difference in STAT1 phosphorylation was most
pronounced at suboptimal concentrations of IFN-a. As shown
in Figure 2c, IFN-a-induced activation of STAT1 was
inhibited in psoriatic T cells transfected with SOCS3
compared with cells transfected with an empty vector.
Moreover, the SOCS3-mediated inhibition was observed at
all IFN-a concentrations tested. In conclusion, these findings
provide evidence that the IFN-a signaling pathway in
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psoriatic T cells is sensitive to inhibition by SOCS3. There-
fore, the prolonged IFN-a-mediated STAT activation in
psoriatic T cells may well stem from a deficient induction
of SOCS3. However, these findings do not explain the
differences in immediate JAK/STAT signaling between psor-
iatic and nonpsoriatic T cells (Figure 2d).
Immediate/early IFN-a-mediated JAK/STAT signaling
correlates with a decreased baseline expression of SHP-1
SH2-domain-containing protein-tyrosine phosphatase is a
tyrosine phosphatase involved in the regulation of JAK/STAT
signaling. As shown in Figure 3a, the expression of SHP-1
was clearly lower in psoriatic T cells when compared with
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Figure 1. Decreased IFN-a-induced SOCS3 mRNA expression in psoriatic T cells. (a) CD8þ T cells from involved skin of a psoriatic patient, Psor-2, and CD8þ
skin-infiltrating control T cells from a nonpsoriatic donor, Control-2, were incubated with IFN-a (5.000 Units ml1) for the indicated periods of time and subjected to
quantification of SOCS3 mRNA expression using RNase protection assay. Data are shown for radiolabeled antisense RNA probes specific for SOCS3 mRNA, and for
mRNA for the housekeeping protein GAPDH. (b) Band intensities from gels (as in panel a) were quantified by PhosphorImager and calculated relative to GAPDH
expression and subtracted from the intensity value of nonstimulated cells. Results are shown as mean values±SD from three independent experiments with
psoriatic T cells from three psoriatic patients (Psor-2, Psor-3, and Psor-16). (c) Stimulated cells from the experiment in panel a were also lysed, and total cell lysates
were subjected to western blotting using an Ab recognizing tyrosine-phosphorylated STAT1 (PY-STAT1). The blot was subsequently stripped and reprobed with
the indicated Abs. (d) Psor-19 and Control-1 T cells were incubated with IFN-a (5,000 Units ml1) for the indicated periods of time and subjected to western
blotting using the indicated Abs. Ab, antibody; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SOCS, suppressor of cytokine signaling.
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control T cells, and was associated with an increase in IFN-a-
induced JAK (JAK1 and TYK2) and STAT (STAT1, STAT2,
and STAT4) activation. The deficient SHP-1 expression in
psoriatic T cells was highly specific because the related
tyrosine phosphate, SHP-2, was expressed at similar levels
compared with control T cells (Figure 3a). The stimulated
T cells were also analyzed by antibody microarray analysis,
which confirmed the increased IFN-a-induced STAT1 phos-
phorylation, together with a decreased SHP-1 (but not SHP-2)
expression in psoriatic T cells when compared with control T
cells (Figures 3b and c). A low SHP-1 expression was also
seen in other psoriatic T-cell lines and short-term cultured
Psor-19 lesional skin T cells (Figure 4a). As shown in Figures
4a and b, the expression of SHP-1 was lower by 2- to 15-fold
in psoriatic T cells when compared with control T cells. To
address whether the decreased expression of SHP-1 was a
unique feature of lesional T cells or a general phenomenon of
psoriatic T cells, we compared the SHP-1 expression in
peripheral blood lymphocytes (PBLs) obtained from psoriasis
patients and healthy donors (see ‘‘Materials and methods’’
section). As shown in Figure 4c, the expression of SHP-1 was
also decreased in PBLs from four different psoriasis patients
when compared with PBLs from four different healthy donors.
Indeed, densiometric measurement of the SHP-1 expression
in Figure 4c, normalized to the corresponding extracellular
signal-regulated kinase expression, showed that SHP-1
expression was significantly decreased (Po0.05) in the group
of psoriatic PBLs compared with the control group (Figure
4d), and that the mean pairwise decrease in SHP-1 expression
was 44% (SEM¼ 9.5).
IFN-a signaling in psoriatic T cells is inhibited by forced
SHP-1 expression
To address whether IFN-a-induced JAK/STAT signaling was
sensitive to regulation by SHP-1, psoriatic T cells were
transiently transfected with SHP-1 or an empty vector. As
shown in Figure 5, IFN-a-induced activation of STAT1 was
significantly inhibited in psoriatic T cells transfected with
SHP-1 when compared with cells transfected with an empty
vector. Thus, the maximal STAT1 response in SHP-1-
transfected cells was reduced byB40% in SHP-1-transfected
cells (Figure 5), indicating that IFN-a-induced JAK/STAT
signaling in psoriatic T cells was, indeed, sensitive to
regulation by SHP-1.
DISCUSSION
IFN hypersensitivity is a characteristic feature of psoriasis,
and IFN-a is believed to have a direct role in disease
pathogenesis (Hida et al., 2000; Eriksen et al., 2005; Nestle
et al., 2005). However, the molecular basis for IFN-a
hypersensitivity remains largely unknown. In this study, we
show that T cells derived from psoriatic skin lesions display
a deficient expression of negative regulators of IFN-a signal-
ing. Thus, the baseline expression of SHP-1 and the
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Figure 2. Increased SOCS3 expression inhibits IFN-a signaling in psoriatic T cells. (a) Psor-2 cells were incubated with MG132 for 4 hours and stimulated
with IFN-a for 15 minutes as indicated. Total cell lysates were subjected to western blotting using the indicated Abs. (b) Psor-2 and Control-2 cells were
stimulated with the indicated concentrations of IFN-a for 15 minutes and subjected to intracellular staining with PY-STAT1-Ab and analyzed by flow cytometry.
Mean fluorescence intensities (MFIs) are shown as mean values±SD from three independent experiments. (c) Psor-2 cells were transiently transfected with
HA-tagged SOCS3 expression vector or HA-tagged empty vector and stimulated with the indicated concentrations of IFN-a for 15 minutes. Cells were then
subjected to intracellular staining with PY-STAT1- and HA-Ab and analyzed by flow cytometry. Fold change in MFIs of IFN-a-induced PY-STAT1 in HA-positive
cells relative to the value of nonstimulated cells is shown as mean values±SD from three independent experiments. (d) Psor-3 and Control-1 cells were
stimulated with IFN-a (5,000 Units ml1) for the indicated periods of time and subjected to western blot analysis using the indicated Abs. Data were
representative of at least three independent experiments. PY-STAT, tyrosine-phosphorylated STAT; SOCS, suppressor of cytokine signaling; STAT, signal
transducer and activator of transcription.
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IFN-a-mediated induction of SOCS3 expression were
significantly lower in psoriatic T cells when compared with
nonpsoriatic-skin T cells. The deficient expression of these
negative regulators seemed to be highly specific, as the
protein expression of SHP-2 and other negative regulators
(data not shown) was not decreased. Importantly, the
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Figure 3. Decreased SHP-1 protein expression in psoriatic T cells. (a) Psor-2 and Control-2 cells were stimulated with IFN-a (5,000 Units ml1) for the
indicated periods of time and subjected to western blot analysis using the indicated Abs. Data are representative of five independent experiments. (b) Total cell
lysates from stimulated (15 minutes) and nonstimulated cells from panel a were subjected to antibody microarray analysis. Normalized signal intensity of
PY-STAT1 protein in IFN-a-stimulated cells is shown as percentage of increase compared with nonstimulated cells. (c) Total cell lysates from nonstimulated cells
from panel a were subjected to antibody microarray analysis. Normalized signal intensity is shown for the indicated proteins. PY-STAT, tyrosine-phosphorylated
STAT; SHP-1, SH2-domain-containing protein-tyrosine phosphatase 1; STAT, signal transducer and activator of transcription.
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Figure 4. Decreased SHP-1 protein expression in T cells from skin and blood of psoriatic patients. (a) T cells from affected skin of different psoriatic
patients (Psor-3, Psor-19, Psor-3063, and Psor-2) and from skin and blood of nonpsoriatic donors (Control-1, Control-3, and peripheral blood lymphocytes
(PBLs)) were subjected to western blotting using the indicated Abs. Data are representative of two independent experiments (b) Band intensities from the upper
lane in panel a were quantified and shown as background-subtracted values. (c) PBLs from four different psoriasis patients and from four different healthy
control donors were subjected to western blotting using the indicated Abs. (d) Band intensities from the upper lanes in panel c were quantified and normalized to
the quantified average band intensities from the two bands in the lower lanes. Results are then shown as mean values±SD from the four different
psoriatic patients and four different control donors (* indicates a significant change in a one-tailed paired t-test with a P-value of 0.023 using a significance level
of 0.05). SHP-1, SH2-domain-containing protein-tyrosine phosphatase 1.
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deficient expression of SHP-1 and SOCS3 in psoriatic T cells
was associated with an increased and prolonged IFN-a-
induced JAK and STAT activation.
The diminished induction of SOCS3 protein was observed
not earlier than 1 hour after IFN-a stimulation (Figure 1).
Therefore, SOCS3 did not seem responsible for the early-
stage increase in IFN-a sensitivity but rather involved the
prolonged STAT activation. The involvement of SOCS3 in the
negative regulation of IFN-a signaling has been previously
demonstrated in several studies on different SOCS3-expres-
sing cell types, either by SOCS3 transfection, cytokine
stimulation, or gene knockdown. Accordingly, SOCS3 has
been found to inhibit IFN-a-mediated STAT1 activation
(Song and Shuai, 1998; Ito et al., 1999; Shen et al., 2000;
Hong et al., 2001; Brender et al., 2001a; Zimmerer et al.,
2007), as well as its antiviral effects (Song and Shuai, 1998).
Furthermore, SOCS3 overexpression confers resistance to
IFN-a therapy in patients with chronic myeloid leukemia,
chronic hepatitis C virus infection, and cutaneous T-cell
lymphoma (Shen et al., 2000; Hong et al., 2001; Brender
et al., 2001a; Sakai et al., 2002; Bode et al., 2003). As both
an increased expression of endogenous SOCS3 after
proteasomal blockade and forced expression of SOCS3
inhibited IFN-a-induced STAT1 phosphorylation, it can
be argued that the IFN-a hypersensitivity in psoriatic T cells
was not due to a resistance to inhibition by SOCS3. Given
our finding of a deficient induction of SOCS3, these
observations further support the notion that the prolonged
STAT response in psoriatic T cells is a result of an insufficient
SOCS3-mediated feedback inhibition of the IFN-a signaling
pathway.
The cytokine-induced expression of SOCS3 can be
mediated by STAT1 (Gatto et al., 2004) and IFN-a triggers
an enhanced activation of STAT1-dependent effector func-
tions in psoriatic T cells (Eriksen et al., 2005). Therefore, it
was unexpected that an increased STAT1 activation was
associated with a decreased induction of SOCS3 in psoriatic
T cells. We looked for, but did not find, a deficient expression
of downstream signaling molecules such IFN regulatory
factor-9 that participate in the formation of the so-called
IFN-stimulated gene factor 3 complex, together with acti-
vated STAT1 and STAT2.
As forced expression of SHP-1 inhibited IFN-a-mediated
STAT activation, it is reasonable to assume that the increased
IFN-a signaling in psoriatic T cells is not caused by a
resistance to SHP-1 inhibition. Given the decreased expres-
sion of SHP-1, our findings suggest that IFN-a hypersensitivity
is, at least in part, due to a deficient expression of SHP-1. This
notion is in agreement with studies by David et al. (1995),
who showed that ‘‘moth-eaten’’ mice lacking functional
SHP-1 display IFN-a hypersensitivity and enhanced JAK/STAT
activation, as well as develop chronic inflammation and
systemic autoimmunity. Recently, Hida et al. provided
evidence for a direct link between increased IFN-a sensitivity
and the development of chronic skin inflammation. Thus,
mice lacking IFN regulatory factor-2 spontaneously devel-
oped psoriasis-like inflammatory skin disease. The condition
was a direct result of excessive IFN-a signaling and depended
on skin-infiltrating CD8þ T cells (Hida et al., 2000). If these
findings apply to humans, they support the idea that a
deficient expression or function of negative regulators of
IFN-a signaling may also cause skin inflammation in psoriatic
patients.
In conclusion, we provide the first evidence of a deficient
expression of SHP-1 and SOCS3 in psoriatic T cells. Thus, our
data support and extend the hypothesis that a loss of
regulatory control of IFN-a signaling is involved in the
pathogenesis of psoriasis.
MATERIALS AND METHODS
Antibodies and other reagents
Recombinant human IFN-a (IntronA) was obtained from Schering-
Plough (Kenilworth, NJ). Recombinant human IL-2 (Proleukin) was
from Chiron (Emeryville, CA). Recombinant human IL-4, phycoer-
ythrin-conjugated rabbit anti-human HA, and phycoerythrin-
conjugated IgG1, IgG2a, and IgG2b isotype controls were from
Leinco Technologies (St Louis, MO). Alexa Fluor 488-conjugated
rabbit anti-human phospho-specific STAT1 (Tyr701) monoclonal
antibody, Alexa Fluor 488-conjugated swine anti-rabbit polyclonal
Ab (pAb), and phospho-specific pAbs against STAT1 (Tyr701), JAK1
(Tyr1022/1023), and TYK2 (Tyr1054/1055) were from Cell
Signaling Technology (Beverly, MA). Phospho-specific STAT2
(Tyr689) pAb was from Upstate Biotechnology (Lake Placid, NY).
Phospho-specific STAT4 (Tyr693) pAb and monoclonal antibody
against STAT4 was from Zymed Laboratories (San Francisco, CA).
STAT1 (E23), STAT2 (C-20), STAT3 (C-20), extracellular signal-
regulated kinase-1/2 (K-23), JAK1 (H-106), TYK2 (C-20), SHP-1
(G-20), and SHP-2 (C-18) pAbs were from Santa Cruz Biotechnology
(Santa Cruz, CA). The rabbit anti-human SOCS3 monoclonal
antibody was from Abcam plc (Cambridge, UK). MG132
was from BIOMOL International, LP (Exeter, UK). The enhanced
chemiluminescence kit was from Miltenyi Biotech (Bergish Glad-
bach, Germany). The human SOCS multiprobe template set used
for the RNase protection assay was from Becton Dickinson
Biosciences (San Jose, CA).
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Figure 5. Increased SHP-1 expression inhibits IFN-a signaling in psoriatic
T cells. Psor-2 cells were transiently transfected with HA-tagged SHP-1
expression vector or HA-tagged empty vector and stimulated with the
indicated concentrations of IFN-a for 15 minutes. Cells were then subjected to
intracellular staining with PY-STAT1 and HA Ab and analyzed by flow
cytometry. Fold change in mean fluorescence intensities (MFIs) of
IFN-a-induced PY-STAT1 in HA-positive cells relative to the value of
nonstimulated cells is shown as mean values±SD from three independent
experiments. HA, hemagglutinin; PY-STAT, tyrosine-phosphorylated STAT;
SHP-1, SH2-domain-containing protein-tyrosine phosphatase 1; STAT, signal
transducer and activator of transcription.
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Subjects
All subjects enrolled in this study have had no antipsoriatic treatment
of any kind for 2 weeks and no systemic antipsoriatic treatment for at
least 4 weeks before the biopsies. They also had no concurrent
infections or medications. The enrolment of subjects and all
experimental procedures were carried out under protocols approved
by the medical ethical committees of each participating institution
and informed written consent was obtained from all subjects. All
experimental procedures were conducted according to the Declara-
tion of Helsinki protocols.
T-cell lines
Psoriatic T-cell lines, Psor-2, Psor-3, Psor-3063, and Psor-16, and the
psoriatic T cell Psor-19, were obtained from skin biopsy samples
from five different patients. The T-cell lines, Control-1, Control-2,
and Control-3, were obtained from skin biopsy samples from three
different patients with diseases other than psoriasis. Biopsy samples
from psoriatic patients were obtained from the center of lesions with
stable chronic plaques. Psor-2, Psor-3, and Psor-3063 were
continuous CD8þ /CD4/IFNARþ /CD25þ /CD45ROþ /CD45RA
T-cell lines established from punch biopsy specimens obtained from
three different patients with psoriasis vulgaris as described previously
(Eriksen et al., 2005). The human T-cell line, CD8/CD4þ /IFNARþ /
CD25þ /CD45ROþ /CD45RA Psor-16, from a psoriatic patient was
established from punch biopsy specimens of a patient with psoriasis
vulgaris as described previously (Skov et al., 1997). Psor-19 cells
are psoriatic CD8/CD4þ /IFNARþ /CD25þ /CD45ROþ /CD45RA
T cells from skin lesions of a psoriatic patient that migrated from
biopsy fragments grown for up to 2 weeks. The human CD8þ /CD4/
IFNARþ /CD25þ /CD45ROþ /CD45RA T-cell lines, Control-1, Con-
trol-2, and Control-3, are continuous T-cell lines derived from
uninfected skin of three different patients with diseases other than
psoriasis as described previously (Eriksen et al., 2005; Woetmann
et al., 2007). Alloreactive human IFNARþ /CD25þ T-cell lines
(referred to as PBL in Figure 5) were obtained from the blood
of healthy individuals and have previously been described
(Eriksen et al., 2005). PBLs from blood of four different psoriasis
patients and from four different healthy control donors were isolated
as described previously (Eriksen et al., 2005). FACS analysis
of psoriasis and control PBLs revealed a comparable amount of
CD3þ cells, and B70% of the cells were CD3þ . The different
psoriasis T-cell lines primarily have a Th1-cytokine profile (Nielsen
et al., 1998, data not shown), and all cells from both control and
psoriasis patients respond equally well to growth factors, such as
IL-2, IL-4, IL-7, and IL-15. Cells were cultured in RPMI 1640 (Sigma,
St Louis, MO) supplemented with 2 mM L-glutamine, 100 mg ml1
penicillin, 100mg ml1 streptomycin (Sigma), 10% pooled human
serum, 1,000 Units ml1 IL-2, and 10 ng ml1 IL-4. The cells were
washed twice and starved for IL-2 and IL-4 for 16–18 hours before
initiation of the experiments.
Protein extraction and western blotting
Protein extraction and the western blotting procedure are described
in detail elsewhere (Krejsgaard et al., 2009). To ensure equal
loading, the total protein concentration of each sample was
determined using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).
Blots were evaluated using enhanced chemiluminescence, and
stripped and reprobed according to the manufacturer’s manual
(Miltenyi Biotech). Subsequent quantifications of band intensities
were performed using ImageMaster Totallab version 2.0 (Amersham
Biosciences/GE Healthcare (Buckinghamshire, UK)).
Intracellular staining and flow cytometry
Intracellular staining of cells with Alexa Fluor 488-conjugated
antibody was performed according to the manufacturer’s protocol
(Cell Signaling Technology). Staining of cells for analysis of cell
surface expression was performed as described previously (Eriksen
et al., 2005). Intracellular and cell surface-stained cells were
analyzed on FACScan using CellQuest software (both from Becton
Dickinson).
Antibody microarray
Stimulated cells were lysed and protein concentration was mea-
sured. Cell lysates were sent for antibody microarray analysis to
Kinexus Bioinformatics Corporation (Vancouver, BC, Canada). The
analysis was performed as described at http://www.kinexus.ca.
RNase protection assay
RNA extraction was performed using the QIAshredder and RNeasy
Mini Kits from Qiagen (Hilden, Germany) according to the
manufacturer’s manual. The purity and size distribution of total
RNA were determined by agarose gel electrophoresis. RNase
protection assay was performed using the ribonuclease protection
kit and the in vitro transcription kit according to the manufacturer’s
protocol (Ambion, Austin, TX). GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) was used as an internal standard, and the
relative SOCS3 expression was calculated as SOCS3/GAPDH
(stimulated cells)SOCS3/GAPDH (nonstimulated cells).
Transient transfections
Transient transfection of Psor-2 cells with HA-tagged SOCS3 and
SHP-1 expression vectors, as well as HA-tagged empty vectors, was
performed as described previously (Eriksen et al., 2009). After
transfection, cells were counted and evaluated, and no difference
was observed between cells transfected with SOCS3/SHP-1 vector or
empty vector. Transiently transfected cells were then stimulated with
IFN-a as indicated, and IFN-a-induced STAT1 phosphorylation was
measured in HA-positive cells by intracellular flow cytometric
analysis as described above.
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